Dr Timi Oshodi joined OncoArendi Therapeutics

OncoArendi Therapeutics – a biotechnology company specializing in the discovery, development and commercialization of innovative drugs, has hired Dr. Timi Oshodi as Director of Preclinical Development. Dr. Oshodi will be responsible for planning and implementing of preclinical safety and pharmacokinetic studies for molecules developed by the company.

Magda KućmaDr Timi Oshodi joined OncoArendi Therapeutics
Czytaj więcej

A new series of publications about the future prospects and development of Polish biotechnology sector was released by Technology Transfer and Entrepreneurship

A new series of publications about the future prospects and development of Polish biotechnology sector was released by Technology Transfer and Entrepreneurship, including case study of #OncoArendi Therapeutics authored by Marcin Szumowski

Magda KućmaA new series of publications about the future prospects and development of Polish biotechnology sector was released by Technology Transfer and Entrepreneurship
Czytaj więcej

OncoArendi Therapeutics has completed a Phase Ib clinical trial with an innovative small molecule experimental drug – OATD-01. Further analyses of the data from the study will lead to the final report and advancing to phase II clinical trials in patients

OncoArendi Therapeutics – a clinical stage biotechnology company specializing in the discovery and development of innovative small molecule drugs continues the clinical development of its first-in-class experimental drug candidate for treatment of sarcoidosis and idiopathic pulmonary fibrosis (IPF). OncoArendi Therapeutics is the first and thus far the only biotechnology company in the world conducting clinical research on new drugs blocking the activity of chitinase proteins.

OncoArendi Therapeutics announces the end of the clinical part of phase Ib trial (multiple ascending dose (MAD)) of the OATD-01 compound after confirming the tolerability of the tested doses and achieving the estimated pharmacodynamic effect. This was the second early phase clinical study after the successfully completed phase Ia “First in Human study” (single ascending dose – SAD).

Magda KućmaOncoArendi Therapeutics has completed a Phase Ib clinical trial with an innovative small molecule experimental drug – OATD-01. Further analyses of the data from the study will lead to the final report and advancing to phase II clinical trials in patients
Czytaj więcej

Drug Candidate OATD-01 may find use in treatment of pulmonary fibrosis in patients who have survived a new coronavirus infection (COVID-19)

  • Potential effectiveness of OATD-01 in the treatment of pulmonary fibrosis is based on a unique mechanism of inhibiting a new biological target – chitotriosidase 1 (CHIT1)
  • Linking COVID-19 infection to pulmonary fibrosis where CHIT1 plays a role will increase the value of OATD-01 and other chitinase inhibitors for potential partners
Magda KućmaDrug Candidate OATD-01 may find use in treatment of pulmonary fibrosis in patients who have survived a new coronavirus infection (COVID-19)
Czytaj więcej

National Center for Research and Development (NCBR) funds OncoArendi Therapeutics’ new research platform of innovative anticancer drugs targeting deubiquitinase proteins.

A proposal submitted by OncoArendi Therapeutics in the Innovative Development Operational Programme (POIR) call for proposals for funding a research project – “RESEARCH AND DEVELOPMENT OF DEUBIQUITINASE INHIBITORS IN ANTITUMOR IMMUNOTHERAPY”, was recommended for funding in the official list published by the National Center for Research and Development (NCBR). The total budget of the project is approx. 31 million PLN, with the amount of funding over 22 million PLN.

Magda KućmaNational Center for Research and Development (NCBR) funds OncoArendi Therapeutics’ new research platform of innovative anticancer drugs targeting deubiquitinase proteins.
Czytaj więcej

New Head of Research (Chief Scientific Officer) at OncoArendi

OncoArendi has recently hired dr. Rafał Kamiński for the position of Chief Scientific Officer. He has acquired broad international experience in discovery and development of innovative small molecule drugs and management of scientific teams from previous work for global pharmaceutical companies. Immediately prior to accepting the CSO position at OncoArendi Therapeutics, dr. Kamiński worked for the Roche Group (Basel, Switzerland).

Magda KućmaNew Head of Research (Chief Scientific Officer) at OncoArendi
Czytaj więcej

First clinical proof-of-concept for arginase inhibitors in cancer immunotherapy

Data presented at the European Society of Medical Oncology (ESMO) in Barcelona by Calithera Biosciences, a biotechnology company from California, USA, add to a growing body of evidence indicating that arginase inhibitors could emerge as novel cancer immunotherapies.

A small molecule drug candidate (INCB001158), licensed by Calithera to Incyte Corporation, is the first arginase inhibitor currently in clinical development. On September 29th Calithera Biosciences presented results of a phase I clinical study of their small molecule drug candidate. In this safety and tolerability study, patients with metastatic or locally advanced cancers, not amendable to available therapies, were treated with INCB001158. Cancer types included lung cancer, colorectal cancer and other solid tumors. INCB1158 was well tolerated and inhibited plasma arginase activity, inducing increased plasma arginine levels at all doses tested.

Magda KućmaFirst clinical proof-of-concept for arginase inhibitors in cancer immunotherapy
Czytaj więcej

OncoArendi Therapeutics at the 2019 BIO International Convention in USA

From June 3 to 6, 2019, OncoArendi Therapeutics will present and promote its programs during the 2019 BIO International Convention in Philadelphia, USA, recognized as one of the world’s most important events in the biotechnology and pharmaceutical industry. Over 16,000 participants from 67 countries will attend the conference.

OncoArendi represented by: Marcin Szumowski, CEO, Nicolas Beuzen, Director of Business Development and Pawel Dobrzanski, Senior Scientific Director has over 40 formally accepted meetings, during which two of the Company’s most advanced assets will be presented:

  • OATD-01, a drug developed in inflammation-driven fibrotic diseases currently completing phase Ib of clinical development, as well as
  • OATD-02, an arginase inhibitor for cancer treatment, currently completing IND-enabling studies.

– During this event we will meet new prospects potentially interested in global or regional (i.e. Asian) rights, and continue ongoing discussions, initiated at previous events, some already under confidentiality agreements. At the same time scouting will be conducted to identify novel molecules that could complement our portfolio of early stage programssays Marcin Szumowski, CEO OncoArendi Therapeutics.

We are keeping our eye on the global biotechnology market that grows at an increasing pace. Many new innovative ideas appear in areas directly related to research projects currently pursued by OncoArendi. Inhibitors of deubiquitinases, a family of proteins representing potential targets in cancer therapy is just one example. These targets have been recently pursued by several mid-size biotech companies, confirming the attractiveness of these new molecular targets in treatment of various diseases.

More information about the 2019 BIO International Convention at: https://convention.bio.org/2019/

Magda KućmaOncoArendi Therapeutics at the 2019 BIO International Convention in USA
Czytaj więcej

OncoArendi at the conference “WSE Innovation Day”

We welcome you to the presentation of OncoArendi Therapeutics, which will take place on April 2, 2019 at the “WSE Innovation Day” conference

“WSE Innovation Day” is a free conference, during which representatives of companies from the new technologies, games or biotechnology sectors will meet with institutional investors, while at the same time meeting with individual investors. The organizers of this year’s edition of the conference are the Warsaw Stock Exchange and Vestor Dom Maklerski.

Details of the conference can be found at https://bit.ly/2HvnZ7L

The conference will be held at the head office of the Warsaw Stock Exchange, ul. Książęca 4.

Admission to the event is free, but requires registration.

Registration form: https://www.gpw.pl/innovationday

 

Magda KućmaOncoArendi at the conference “WSE Innovation Day”
Czytaj więcej

OncoArendi Therapeutics wins the award of the Stock Exchange “Company of the Year” competition 2018

In the ranking of the Listed Company of the Year, organized by Puls Biznesu and Bankier.pl, OncoArendi Therapeutics took second place in the category “Innovation in products and services”.

“We are pleased with the distinction and recognition by the capital market of OncoArendi Therapeutics’ innovative research and development of new drugs. This is a great success for a company which has been listed on the stock exchange for less than a year, and yet has overtaken many larger companies in the ranking, with much longer stock exchange experience. This is the reward of the whole OncoArendi team, whose passion and commitment and daily, hard work brings us closer to the goal set “- says Marcin Szumowski, president and significant shareholder of OncoArendi Therapeutics.

The ranking was based on surveys sent to nearly 100 analysts, managers and brokers, who selected and evaluated the best companies listed on the Warsaw Stock Exchange on five categories: board competence, investor relations, success in 2018, development prospects and innovation of products and services.

In the overall ranking, OncoArendi Therapeutics has been ranked 21st out of the top 30 rated companies from the WSE main market.

Information on the ranking on the website: https://www.pb.pl/gsr/o-rankingu

Magda KućmaOncoArendi Therapeutics wins the award of the Stock Exchange “Company of the Year” competition 2018
Czytaj więcej